Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID)

Mark James Ponsford, Rachael Steven, Kathyrn Bramhall, Mathew Burgess, Sonali Wijetilleka, Emily Carne, Frances McGuire, Colin R Price, Mo Moody, Soha Zouwail, Tayeb Tahir, Daniel Farewell, Tariq El-Shanawany, Stephen R A Jolles

Abstract

Aims An association between antibody deficiency and clozapine use in individuals with schizophrenia has recently been reported. We hypothesised that if clozapine-associated hypogammaglobulinaemia was clinically relevant this would manifest in referral patterns.

Methods Retrospective case note review of patients referred and assessed by Immunology Centre for Wales (ICW) between January 2005 and July 2018 with extraction of clinical and immunological features for individuals with diagnosis of schizophrenia-like illness.

Results 1791 adult patients were assessed at ICW during this period; 23 patients had a psychiatric diagnosis of schizophrenia or schizoaffective disorder. Principal indications for referral were findings of low calculated globulin and immunoglobulins. Clozapine was the single most commonly prescribed antipsychotic (17/23), disproportionately increased relative to reported use in the general schizophrenia population (OR 6.48, 95% CI: 1.79 to 23.5). Clozapine therapy was noted in 6/7 (86%) of patients subsequently requiring immunoglobulin replacement therapy (IgRT). Marked reduction of class-switched memory B cells (CSMB) and plasmablasts were observed in clozapine-treated individuals relative to healthy age-matched controls. Clozapine duration is associated with CSMB decline. One patient discontinued clozapine, with gradual recovery of IgG levels without use of IgRT.

Conclusions Our findings are consistent with enrichment of clozapine-treatment within schizophrenic individuals referred for ICW assessment over the last 13 years. These individuals displayed clinical patterns closely resembling the primary immunodeficiency common variable immunodeficiency, however appears reversible on drug cessation. This has diagnostic, monitoring and treatment implications for psychiatry and immunology teams and directs prospective studies to address causality and the wider implications for this patient group.

Introduction

Schizophrenia is an enduring major psychiatric disorder affecting around 1% of the population. In addition to the debilitating psychiatric symptoms, it has major psychosocial consequences with an unemployment rate of 80%–90% and a life expectancy reduced by 10–20 years including suicide rates of approximately 5%. Societal costs in England alone are estimated to be £11·8 billion per year. Clozapine is a dibenzo-diazepine antipsychotic and the only licensed medication, for approximately 30% of patients with treatment-resistant schizophrenia (TRS). There is increasing evidence linking clozapine with pneumonia-related admissions and mortality. Postulated mechanisms include sialorrhoea, sedation, agranulocytosis and aspiration. We recently reported an association between clozapine therapy in schizophrenia and hypogammaglobulinaemia, greater than that reported following rituximab and methotrexate therapy in rheumatoid arthritis. To better define the clinical and immunological abnormalities associated with clozapine use, we performed a retrospective case review of patients assessed at the Immunology Centre for Wales (ICW).

Methods

Electronic case records for patients assessed at ICW between January 2005 and July 2018 to identify all individuals with a concomitant psychiatric diagnosis of schizophrenia or schizoaffective disorder. Indication for referral, medication and comorbidities, and immunological testing at initial assessment and treatments were extracted using a standardised proforma. Recurrent infection history was defined as ≥3 distinct antibiotic courses per year or serious infection requiring admission, as in the wider literature.

All testing was performed in the United Kingdom Accreditation Service-accredited Medical Biochemistry & Immunology Laboratory at the University Hospital of Wales. Immunoglobulin levels (IgG, IgA and IgM) were assayed by nephelometry (Siemens BN2 Nephelometer; Siemens), serum electrophoresis (Sebia Capillars 2; Sebia, Norcross, Georgia, USA) and, where appropriate, serum immunofixation performed (Sebia Hydrasys; Sebia).
Original research

Antibody titres against *Haemophilus influenzae* and *Streptococcus pneumoniae* capsular polysaccharide and tetanus toxoid were determined by ELISA (The Binding Site, Birmingham, UK). Flow cytometry was performed using Beckman Coulter FC500 analyser. Lymphocyte phenotypes were analysed using Beckman Coulter Cyto-star Tetrachrome reagents (CD45-FTC; CD4-RD1/CD8-ECD/CD3-PCS and CD45-FTC/CD56-RD1/CD10-ECD/CD3-PCS), Flow-Count Fluorospheres and vasa-lysis solution. B-cell phenotyping was performed as previously described using the following antibodies: CD19-P/ Cy7 (Beckman Coulter), CD27-FITC (Serotec), CD21-PE (BD Pharmingen), CD38-FITC (Beckman Coulter), IgM Alexa-Flour 647 (Jackson ImmunoResearch), IgD-PE (Southern Biotech). Common variable immunodeficiency (CVID) and age-matched healthy controls were analysed as part of an anonymous sample exchange scheme run jointly with King’s College London. Reference ranges are provided within the text. Individual clinical, immune and treatment data are available in online supplementary file S1.

STATISTICAL ANALYSIS

Data were curated in Microsoft Excel. Fisher’s exact test and non-parametric Mann-Whitney U test, following D’Agostino and Pearson normality assessment, and curve fitting were conducted using GraphPad Prism V.6.07. Where immunoglobulin level was undetectable, the lower limit of detection (IgG 1.34 g/L; IgA 0.053 g/L and IgM 0.053 g/L) was used for data analysis, with density estimation and plotting performed in R (V.3.4.0). A two-tailed significance level of p<0.05 was used.

RESULTS

Enrichment of clozapine-treated patients within schizophrenia cases referred for immunology assessment and requiring immunoglobulin replacement therapy.

During the evaluation period, 1791 adults were assessed at ICW; 23 had a diagnosis of schizophrenia or schizoaffective disorders. We hypothesised that if clozapine-associated hypogammaglobulinaemia was clinically relevant, this would manifest in referral patterns. The mean clozapine prescription (online supplementary table 1) rate reported by the 2014 UK National Audit of Schizophrenia was 30%. We therefore expected a ratio of 7 clozapine:16 non-clozapine users. In contrast, we observed 17 patients with a history of clozapine use, corresponding to an OR of 6.48 (95% CI: 2.0–21.7), p=0.0072. This remained significant for prevalence estimates of clozapine use among the Welsh schizophrenia population up to 43% (online supplementary file S2). Patients receiving clozapine accounted for 6/7 (86%) of schizophrenia cases requiring immuno-globulin replacement therapy (IgRT), approximately 3% of our adult IgRT cohort. This compares with the international schizophrenia prevalence of 0.4–1%. This suggests enrichment of clozapine-treated patients within our immunodeficiency cohort relative to the general population.

We next explored indication for referral and immunological finding at first assessment (individual patient details summarised—online supplementary file S1). Two clozapine-treatment patient with hypogammaglobulinaemia have been previously identified and reported. Recurrent infection was documented in 10/17 subjects (59%), predominately reflecting sinusopulmonary infections. Four patients (24%) were referred with serum antibody levels below the fifth percentile without any antibiotic use in the preceding 12 months (summarised—table 1). A low calculated globulin (CG) (<23 g/L) was present in 15/17 (88%) of subjects receiving clozapine and was associated with reductions in IgG, IgA and IgM below the fifth percentiles in 14/17 subjects. We also found referral rates increased following the national introduction of CG screening to Wales during 2014, and prior to release of our initial report (online supplementary file S3). Consistent with CG reduction, serum immunoglobulin levels were also reduced (summarised in figure 1). Taken together, this is consistent with a clozapine-specific association with dysgammaglobulinaemia, and the utility of CG screening to stratify patients for specialist immunology assessment.

See online supplementary file S1 for individual patient values.

B-cell dysregulation associated with long-term clozapine use resembles CVID

Clozapine users are closely monitored for side effects of neutro-penia and agranulocytosis, and all individuals showed normal neutrophil counts at first assessment. Lymphopaenia and reduction in T cells were present but largely confined to two individuals subsequently diagnosed with haematological malignancies (table 1; online supplementary file S2). Because the mechanisms underlying clozapine-associated hypogammaglobulinaemia remain unknown, we focused on B-cell clinical immunopheno-typing data performed in isolation or as part of a full EUROClass evaluation. We took advantage of existing laboratory data to identify age-matched individuals with CVID (n=26) and healthy controls (n=16) to clozapine-treated patients (following exclusion of cases with haematological malignancy, n=15). Clozapine-treated individuals showed normal total and naive B-cell counts (Figure 2A) but reduction of class-switched memory B cells (CSMB) relative to healthy individuals (Mann-Whitney U test, p<0.0001), with the exception of a single patient who had discontinued clozapine after a 2-month trial and had normal immunoglobulin levels (figure 2B; online supplementary file S2).

### Table 1 Immunology assessment summary at initial clinical visit

<table>
<thead>
<tr>
<th>Schizophrenia with history of clozapine use (median, range)</th>
<th>Adult reference range (5th–95th percentile unless indicated*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>17</td>
</tr>
<tr>
<td>Age, years (median, range)</td>
<td>50 (36–63)</td>
</tr>
<tr>
<td>Gender (M:F)</td>
<td>11:6</td>
</tr>
<tr>
<td>Neutrophils (median, range)</td>
<td>4.3 (2.0–10.2)</td>
</tr>
<tr>
<td>Lymphocytes (median, range)</td>
<td>1.3 (0.8–2.1)</td>
</tr>
<tr>
<td>IgG</td>
<td>3.20 (1.20–6.65)</td>
</tr>
<tr>
<td>IgA</td>
<td>0.26 (0.05–0.81)</td>
</tr>
<tr>
<td>IgM</td>
<td>0.17 (0.05–0.64)</td>
</tr>
<tr>
<td>CD3+ T cells</td>
<td>930 (380–1960)</td>
</tr>
<tr>
<td>CD3+CD4+ T helper cells</td>
<td>600 (110–1350)</td>
</tr>
<tr>
<td>CD3+CD8+ cytotoxic T cells</td>
<td>230 (60–560)</td>
</tr>
<tr>
<td>CD19+ B cells</td>
<td>260 (100–450)</td>
</tr>
<tr>
<td>CD56+ natural killer cells</td>
<td>90 (20–460)</td>
</tr>
<tr>
<td>Naive B cells (%B) (n=14)</td>
<td>83.8 (23.6–95.8)</td>
</tr>
<tr>
<td>Marginal zone-like B cells (%B) (n=14)</td>
<td>11.0 (3.1–71.2)</td>
</tr>
<tr>
<td>Class-switched memory B cells (%B) (n=16)</td>
<td>1.6 (0.2–11.6)</td>
</tr>
<tr>
<td>Plasmablasts (%B) (n=6)</td>
<td>0.01 (0–0.04)</td>
</tr>
</tbody>
</table>

Reference ranges for immunoglobulins and lymphocyte subsets represent 5th–95th percentiles. *B cell adult reference ranges represent interquartile range (adapted from Morbach et al). See also online supplementary table 1 for individual values.
Immunophenotyping of plasmablasts was available for six individuals receiving clozapine and was comparable to CVID (Figure 2C), but significantly reduced compared with age-matched healthy controls (Mann-Whitney U test, p=0.004). We observed a general decline in CSMB with increasing duration of clozapine therapy (figure 2D), which appears independent of age (online supplementary file S4).

Vaccine-specific IgG responses are routinely evaluated as part of clinical assessment. At initial assessment, levels below putative protective thresholds were common with IgG to *H. influenzae* B (HiB) <1 μg/mL in 12/16 assessed (75%); Pneumococcal-IgG <50 mg/L in 15/16 (94%) and tetanus-IgG <0.1 IU/mL in 6/16 (38%) individuals tested. Post-Menitorix (HiB/MenC conjugated to tetanus toxoid) vaccination serology was assessed after 4 weeks, with 5/11 (45%) individuals failing to mount a HiB-IgG response ≥1 μg/mL, and 1/12 failing to exceed the ≥0.10 IU/mL postvaccination tetanus-IgG level defined by WHO. Following Pneumovax II, 6/16 (38%) individuals failed to develop an IgG response above a threshold of ≥50 mg/L (see online supplementary file S1 and online supplementary file S5 for vaccine response assessment).

Reduction in infection burden following immunoglobulin replacement therapy

Our approach to antibody deficiency follows the previously reported findings. Cumulative follow-up for clozapine-associated hypogammaglobulinaemia now exceeds 61 patient-years (range 0.5–11 years), during which time 6/16 (38%) of clozapine-treated patients were commenced on IgRT. Over a 12-month period prior to replacement, these patients received a mean of 6.5 acute antibiotic courses (range 3–12, including one inpatient admission requiring parenteral therapy). Following IgRT, this fell to a median of 1.5 oral antibiotics courses per year (range 0–2 courses), with no infection-triggered hospital admissions. Replacement through IgG levels ranged from 5.5 to 9.6 g/L (mean 8.0 g/L).

**Partial recovery of immunoglobulin following clozapine discontinuation**

One patient (online supplementary table S1: IDs #7) discontinued clozapine due to the known side effect of neutropaenia, detected by the clozapine monitoring programme, providing a unique opportunity to examine reversibility of humoral dysregulation. In the absence of IgRT, patient #7 has demonstrated a gradual recovery in terms of serum IgG level from 3.5 to 5.95 g/L over 3 years, however IgA and IgM levels have remained depressed (figure 3). Patient #2 discontinued clozapine 2 years ago, having already commenced IgRT, with subsequent recovery of IgM from 0.22 to 0.86. IgA levels have remained below 0.24 g/L. Together, this provides support for reversibility in humoral function following clozapine-withdrawal, but suggests this process is gradual and limited. In contrast, clozapine cessation in patient #2 was associated with profound and acute relapse of psychiatric symptoms, requiring prolonged inpatient admission to a specialist mental health unit.

**DISCUSSION**

In this retrospective review of referrals to a national immunology centre, we found that individuals with schizophrenia receiving clozapine displayed clinically significant pan-hypogammaglobulinaemia, impaired vaccine responses and disturbed B-cell maturation with a proportion benefitting from IgRT. Consistent with a specific relationship to clozapine...
use, we observed enrichment of clozapine use among patients with schizophrenia undergoing immunology assessment or requiring IgRT relative to that reported in the wider population by a number of recent studies.4 17 24 The most common feature at referral was a low CG. 25 Importantly, both clozapine and non-clozapine antipsychotic medications require routine liver function monitoring, 26 arguing against a referral bias due to differential testing. While the use of CG screening is being developed in a number of countries, a lack of wider availability may limit the identification of antibody-deficient patients taking clozapine in other settings.25 27 28

Our finding of a temporal association between clozapine use and reduction in CSMB is consistent with our previous analysis of a separate cohort that hypogammaglobulinaemia appears a late manifestation of clozapine therapy.12 Our immunological findings associated with clozapine-associated hypogammaglobulinaemia is independently supported by a recently reported peripheral blood immune signature for patients with TRS revealing reduced plasmablasts and CSMB relative to disease and healthy controls.29 While this study focused on psychiatric status, the majority of such patients were clozapine-treated; immunoglobulin levels were not determined by this group.29 These findings also suggest that many clozapine-treated patients in our cohort and beyond may have received a diagnosis of CVID, according to internationally accepted criteria.30 We are conducting a wider survey of UK Immunology centres to examine this observation.

This study has several limitations, including its sample size and single-centre retrospective design. Prospective studies are required, for instance, to validate the association between therapy duration and effect on B-cell phenotypes, and to address causality. We speculate an effect targeting late-stage B-cell differentiation or survival may underlie the observed findings.31 However, at present, we cannot exclude a link to the underlying pathophysiology of schizophrenia, which like CVID remains largely unknown. Intriguingly, pathway analysis of schizophrenia associations have demonstrated marked enrichment at enhancers active in immune tissues, particularly B-lymphocyte lineages.32 Polypharmacy, multimorbidity and socioeconomic status are common and important factors complicating healthcare delivery in schizophrenia33 34 and might also contribute to the observed findings. Smoking is common in both clozapine-treated and clozapine-naïve patients with schizophreniapatients,35 predisposes to pneumonia36 and may lead to systemic steroid therapy for chronic obstructive pulmonary disorder. However, the reduced CSMB and pan-hypogammaglobulinaemia profiles we observed clearly differ from the patterns previously reported with both steroids or smoking.37 38 Other medication including metformin and antiepileptics have been described to have immunomodulatory effects in murine studies39 or case series40; however, do not fully explain the observed hypogammaglobulinaemia—in line with the rigorous exclusion criteria applied during our initial case-control study.12 The immunomodulatory effects of the dibenzodiazepine clozapine are increasingly recognised beyond agranulocytosis and neutropaenia.41-43 Here,
we present evidence of gradual recovery of humoral immune function following clozapine withdrawal in the absence of IgRT.

From a practical standpoint, recovery of immunoglobulin levels appeared gradual and variable. Weighed against the florid relapse in psychiatric symptoms observed following clozapine discontinuation in one, we do not currently suggest discontinuation of clozapine in patients. This is in line with the unique efficacy of clozapine in TRS, and availability of treatment options to mitigate the risks associated with antibody deficiency. Finally, given evidence of increased risk of pneumonia within individuals with schizophrenia, our finding of low levels of baseline immunity to common vaccinations within this patient group highlights a simple strategy for risk mitigation.

Summary

We report the clinical features of clozapine-associated immunodeficiency identified following the introduction of CG screening in Wales and highlight clinically significant panhypogammaglobulinemia, impaired vaccine responses and new findings of disturbed B-cell maturation. In support of a drug-related effect, we show a temporal association between clozapine exposure and reduction in CSMB levels, and evidence of gradual reversibility following discontinuation. Clinicians should be alert for this diagnostic overlap with CVID. Patients may benefit from monitoring or clinical intervention in the form of vaccination, antibiotic prophylaxis or IgRT. Clozapine’s immunomodulatory effects are poorly understood, and further studies are required to delineate mechanism.

Kudos plain language summary

The introduction of clozapine in the 1950s was a major therapeutic advance in the treatment of schizophrenia. It remains the gold standard therapy for approximately 3/10 individuals who fail to respond to initial management. Overall, clozapine improves symptoms and saves lives. Recent studies (2018) have suggested that clozapine therapy may be associated with a block in antibody production (causing antibody deficiency). This would predict patients receiving this therapy to be more likely to experience infections (such as pneumonia). This work examines patients referred to a major immunology centre since 2005, with focus on those receiving antipsychotic medicines (including clozapine). As predicted by the authors (but against the normal pattern of prescribing), clozapine was the most common antipsychotic used by patients referred with antibody deficiency. The authors go on to define the clinical and immunological features of this group, highlighting a close similarity to individuals without a known cause of antibody deficiency. Several clozapine-treated patients went on to receive antibody replacement therapy, successfully reducing their infection rate. By following these patients over time, they also saw that in one patient who stopped clozapine treatment this was associated with a gradual return in their major antibody (IgG). This adds support to the argument that clozapine therapy is associated with a drug-related (secondary) antibody deficiency. This is an important finding for immunologists around the world, who could easily confuse a drug-related cause of antibody deficiency with an inherited (primary) case. The authors remain cautious and suggest further studies are needed with greater size and following patients before and after they start/stop clozapine. This is because the disease processes underlying both schizophrenia and primary antibody deficiency remain largely unknown: meaning there could be important shared mechanisms linking both conditions.

Handling editor Tahir S Pillay.

Twitter Mark James Ponsford @MP50683800

Acknowledgements The authors would like to thank the patients and wider clinical immunology and mental health teams who have contributed, and Dr Mohammad Ibrahim and the King’s College Hospital Immunology team for participating in immunophenotyping sample exchange schemes.

Collaborators Simon A Jones, Ana Cardus Figueras, James Walters.

Contributors MIP and SRAJ conceived study, and performed data extraction and analysis, and wrote the first draft. RS, KB and MB performed immunophenotyping and assisted in data extraction. DP provided support for statistical analysis. SW, EC, FMG, CRP, SZ, TT and TE-S contributed to clinical record extraction and/or interpretation of data. All authors critically reviewed and approved the final version.

Funding This study was funded by Cardiff University (grant number: Welsh Clinical Academic Training Fellowship).

Competing interests MIP is supported by the Welsh Clinical Academic Training Fellowship (WCAT) Programme and received a Wellcome Trust Institutional Strategic Support Fund (ISSSF3) grant (204824Z/16/Z). SRAJ has received support from CSL Behring, Shire, LFB, Biotest, Binding Site, Sanofi, GSK, UCB Pharma, Grifols, BPL SOBi, Weatherden, Zarexoid and Octapharma for projects, advisory boards, meetings, studies, speaker and clinical trials. TE-S has received educational support, support project, advisory board fees, speaker fees and/or clinical trial support from Biotech, CSL, LFB, Mylan, Novartis, Shire and Werfen. CRP has received support to attend educational meetings from CSL Behring and ALK. The remaining authors have no relevant conflicts of interest to declare.

Patient consent for publication Not required.

Ethics approval This work was deemed as service evaluation by the institutional review board and required for ethical approval was waived.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Submission to MEDRxiv (reference: 2019/007815) has been performed in line with JCP/BMJ Policy.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iD
Mark James Ponsford http://orcid.org/0000-0002-0236-1059

REFERENCES
Original research


11 Dyer C. Coroner’s warn health Secretary of clozapine deaths. *BMJ* 2018;363:k5421.


15 Patel SY, Carter D, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. *Front Immunol* 2019;10:.


